ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

CLSD Clearside Biomedical Inc

1,35
0,03 (2,27%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Clearside Biomedical Inc CLSD NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,03 2,27% 1,35 00:09:02
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,34 1,29 1,35 1,31 1,32
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202413:05GLOBEClearside Biomedical to Report First Quarter 2024 Financial..
16/4/202413:05GLOBEClearside Biomedical Appoints Seasoned Biotechnology..
02/4/202413:05GLOBEClearside Biomedical to Participate in Fireside Chat at the..
18/3/202412:05GLOBEClearside Biomedical Appoints Victor Chong, M.D., MBA as..
12/3/202421:05GLOBEClearside Biomedical Announces Fourth Quarter and Full Year..
29/2/202413:05GLOBEClearside Biomedical to Report Fourth Quarter and Full Year..
08/2/202423:05EDGAR2Form 8-K - Current report
08/2/202422:52EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/2/202414:00GLOBEClearside Biomedical Announces Pricing of $15 Million..
01/2/202422:01EDGAR2Form 8-K - Current report
20/1/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202421:04EDGAR2Form 144 - Report of proposed sale of securities
28/12/202322:10EDGAR2Form 8-K - Current report
14/12/202313:05GLOBEClearside Biomedical Reports Significant Progress in ODYSSEY..
13/11/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:10EDGAR2Form 8-K - Current report
13/11/202322:05GLOBEClearside Biomedical Announces Third Quarter 2023 Financial..
08/11/202313:05GLOBEClearside Biomedical to Participate in Fireside Chat at the..
07/11/202322:20GLOBEClearside Biomedical’s Versatile Suprachoroidal Injection..
03/11/202317:01EDGAR2Form 8-K - Current report
03/11/202317:00GLOBEBioCryst and Clearside Biomedical Enter Partnership to..
02/11/202312:05GLOBEClearside Biomedical Announces Presentations at the American..
01/11/202312:05GLOBEClearside Biomedical Completes Recruitment in ODYSSEY Phase..
31/10/202312:05GLOBEClearside Biomedical to Report Third Quarter 2023 Financial..
16/10/202313:05GLOBEClearside Biomedical Positive OASIS and Extension Study Data..
04/10/202315:00GLOBEClearside Biomedical Announces Advancement of XIPERE® in..
03/10/202322:35GLOBEClearside Biomedical to Participate in a Panel Discussion at..
29/9/202322:46EDGAR2Form 8-K - Current report
25/9/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/9/202322:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/9/202313:05GLOBEClearside Biomedical to Participate in Panel Discussion at..
14/9/202300:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:11EDGAR2Form 8-K - Current report
14/8/202322:05GLOBEClearside Biomedical Announces Second Quarter 2023 Financial..
02/8/202322:30GLOBEClearside Biomedical to Participate in Upcoming Investor..
01/8/202313:05GLOBEClearside Biomedical to Report Second Quarter 2023 Financial..
31/7/202313:05GLOBEClearside Biomedical Highlights Excellent Safety Profile of..
20/7/202313:05GLOBEClearside Biomedical’s Suprachoroidal Injection Platform to..
17/7/202313:05GLOBEClearside Biomedical Announces Enrollment of Multiple..
11/7/202322:05GLOBEClearside Biomedical CEO George Lasezkay to Present at the..
10/7/202313:05GLOBEClearside Biomedical Asia-Pacific Partner Arctic Vision..
01/6/202313:05GLOBEClearside Biomedical Opens Enrollment in ODYSSEY Phase 2b..
11/5/202313:05GLOBEClearside Biomedical Announces First Quarter 2023 Financial..
09/5/202322:30GLOBEClearside Biomedical to Participate in a Fireside Chat at..

Dernières Valeurs Consultées

Delayed Upgrade Clock